

10/30/01
JULY 2001
U.S. PTO12-12-01
Book Set

PTO/SB/05 (03-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 39]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 7]
5. Oath or Declaration [Total Pages _____]
 a. Newly executed (original or copy)
 Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. Application Data Sheet. See 37 CFR 1.76

Attorney Docket No.	9525
First Inventor	Tanja Ligensa et al.
Title	IGF-1 Receptor Interacting Proteins
Express Mail Label No.	EL912160928US

ADDRESS TO: Commissioner for Patents
Box Patent Application
Washington, DC 20231
JC 10/30/01

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*
 - a. Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. CD-ROM or CD-R (2 copies); or
 - ii. paper
 - c. Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))
10. 37 CFR 3.73(b) Statement *(when there is an assignee)* Power of Attorney
11. English Translation Document *(if applicable)*
12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
13. Preliminary Amendment
14. Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
15. Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP)

of prior application No.: 09/453,195

Prior application information:


Examiner J. Andres

Group Art Unit: 1646

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	00151	or <input type="checkbox"/> Correspondence address below
Name		
Address		
City	State	Zip Code
Country	Telephone	Fax

Name (Print/Type)	F. Aaron Dubberley	Registration No. (Attorney/Agent)	41001
Signature			
	Date	10/30/2001	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Commissioner for Patents
BOX PATENT APPLICATION
Washington, D.C. 20231

Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley, NJ 07110
Case Docket 9525
October 30, 2001

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the patent application of

Inventor(s): Tanja Ligensa, Ralf Schumacher, Michael Weidner

For: **IGF-1 RECEPTOR INTERACTING PROTEINS**

1. The fee has been calculated as shown below:


CLAIMS				
FOR	NO. FILED	NO. EXTRA	RATE	FEE
TOTAL CLAIMS	14 - 20	0	x \$18	---
INDEP. CLAIMS	3 - 3	0	x \$84	---
MULTIPLE DEPENDENT CLAIMS PRESENTED		+ \$280		
BASIC FEE			\$740	
				TOTAL \$ 740

Please charge Deposit Account No. 08-2525 in the amount noted above.


The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 08-2525, including those under 37 C.F.R. § 1.16 and 1.17. This sheet is provided in duplicate.

Continue to address all communications to:

George W. Johnston
Hoffmann-La Roche Inc.
340 Kingsland Street
Nutley, NJ 07110


Agent for Applicant(s)
F. Aaron Dubberley
(Reg. No. 41001)

115111



Certification under 37 CFR 1.10

I hereby certify that this form and all documents cited on this form are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number:

EL912160928 US

addressed to: **Commissioner for Patents**
Washington, D.C. 20231

on October 30, 2001.

Date


Signature

Marta Swaryczewsky

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Papers Submitted for Case Docket 9525 US: Patent Application Transmittal Form, Application Data Sheet, Fee Transmittal Form, Specification, Sequence Listing, Diskette, Statement Under 37 CFR 1.821 or 1.825, Drawings, Information Disclosure Statement with PTO Form 1449

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Ligensa et al.

Art Unit:
Examiner:

Case Docket 9525
(CIP of Serial No. 09/453,195, filed December 2, 1999)

For: **IGF-1 RECEPTOR INTERACTING PROTEINS**

**STATEMENT
UNDER 37 CFR §1.821 or §1.825**

Nutley, New Jersey 07110
October 30, 2001

Commissioner for Patents
Washington, D.C. 20231


Sir:

I hereby certify that:

- X The contents of the paper Sequence Listing and computer readable Sequence Listing submitted herewith are the same. (37 CFR §1.821(f))
- The contents of the paper Sequence Listing and computer readable Sequence Listing submitted herewith are the same. No new matter is included. (37 CFR §1.821(f) & (g))

- Each of the substituted sheets of the paper Sequence Listing submitted herewith is supported in the captioned application. No new matter is included. (37 CFR §1.825(a))
- The contents of the substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are the same. No new matter is included. (37 CFR §1.825(a) & (b))
- The substitute computer readable Sequence Listing submitted herewith is identical to that originally filed. (37 CFR §1.825(d))
- No computer readable Sequence Listing is being submitted herewith. The content of the paper Sequence Listing submitted herewith is identical to the content of the compliant computer readable Sequence Listing filed _____ in US Patent Application Serial No. _____, filed _____. Applicants request the use of the above compliant computer readable Sequence Listing in the instant application.

Respectfully submitted,



Agent for Applicant(s)
F. Aaron Dubberley
(Reg. No. 41001)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4387
Telefax: (973) 235-2363

115101